-
1
-
-
84855692909
-
-
American Cancer Society
-
[Internet] American Cancer Society. What are the key statistics about melanoma skin cancer? http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics: American Cancer Society; 2014.
-
(2014)
What are the key statistics about melanoma skin cancer?
-
-
-
3
-
-
84866600895
-
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23 Suppl 7: 86-91.
-
(2012)
Annals of oncology: official journal of the European Society for Medical Oncology/ESMO
, vol.23
, pp. 86-91
-
-
Dummer, R.1
Hauschild, A.2
Guggenheim, M.3
Keilholz, U.4
Pentheroudakis, G.5
-
4
-
-
84899490109
-
The role of adjuvant radiotherapy in the local management of desmoplastic melanoma
-
Guadagnolo BA, Prieto V, Weber R, Ross MI, Zagars GK. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer. 2014; 120: 1361-8.
-
(2014)
Cancer
, vol.120
, pp. 1361-1368
-
-
Guadagnolo, B.A.1
Prieto, V.2
Weber, R.3
Ross, M.I.4
Zagars, G.K.5
-
5
-
-
84876707877
-
The role of radiotherapy in the overall treatment of melanoma
-
Forschner A, Heinrich V, Pflugfelder A, Meier F, Garbe C. The role of radiotherapy in the overall treatment of melanoma. Clinics in dermatology. 2013; 31: 282-9.
-
(2013)
Clinics in dermatology
, vol.31
, pp. 282-289
-
-
Forschner, A.1
Heinrich, V.2
Pflugfelder, A.3
Meier, F.4
Garbe, C.5
-
6
-
-
79952613370
-
Systematic review of medical treatment in melanoma: current status and future prospects
-
Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. The oncologist. 2011; 16: 5-24.
-
(2011)
The oncologist
, vol.16
, pp. 5-24
-
-
Garbe, C.1
Eigentler, T.K.2
Keilholz, U.3
Hauschild, A.4
Kirkwood, J.M.5
-
7
-
-
18244365876
-
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
-
Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). British journal of cancer. 2002; 86: 179-84.
-
(2002)
British journal of cancer
, vol.86
, pp. 179-184
-
-
Atzpodien, J.1
Neuber, K.2
Kamanabrou, D.3
Fluck, M.4
Brocker, E.B.5
Neumann, C.6
-
8
-
-
0034777045
-
The role interferon-alpha in malignant melanoma remains to be defined
-
Eggermont AM. The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer. 2001; 37: 2147-53.
-
(2001)
Eur J Cancer
, vol.37
, pp. 2147-2153
-
-
Eggermont, A.M.1
-
9
-
-
84947734356
-
-
[Internet] FDA. Ipilimumab. http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm248478.htm
-
Ipilimumab
-
-
-
10
-
-
84883559055
-
Immunotherapy for advanced melanoma: fulfilling the promise
-
Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer treatment reviews. 2013; 39: 879-85.
-
(2013)
Cancer treatment reviews
, vol.39
, pp. 879-885
-
-
Gogas, H.1
Polyzos, A.2
Kirkwood, J.3
-
12
-
-
84904486880
-
-
[Internet] FDA. Trametinib and Dabrafenib. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm381451.htm
-
Trametinib and Dabrafenib
-
-
-
13
-
-
84945220721
-
-
[Internet] FDA. Nivolumab. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm427807.htm
-
Nivolumab
-
-
-
14
-
-
0346728596
-
Determinants of BRAF mutations in primary melanomas
-
Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. Journal of the National Cancer Institute. 2003; 95: 1878-90.
-
(2003)
Journal of the National Cancer Institute
, vol.95
, pp. 1878-1890
-
-
Maldonado, J.L.1
Fridlyand, J.2
Patel, H.3
Jain, A.N.4
Busam, K.5
Kageshita, T.6
-
15
-
-
2942533921
-
Microarray expression profiling in melanoma reveals a BRAF mutation signature
-
Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 2004; 23: 4060-7.
-
(2004)
Oncogene
, vol.23
, pp. 4060-4067
-
-
Pavey, S.1
Johansson, P.2
Packer, L.3
Taylor, J.4
Stark, M.5
Pollock, P.M.6
-
16
-
-
26444468886
-
Analysis of BRAF mutation in primary and metastatic melanoma
-
Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle. 2005; 4: 1382-4.
-
(2005)
Cell Cycle
, vol.4
, pp. 1382-1384
-
-
Libra, M.1
Malaponte, G.2
Navolanic, P.M.3
Gangemi, P.4
Bevelacqua, V.5
Proietti, L.6
-
18
-
-
84872061126
-
-
[Internet] FDA. Vemurafenib. http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm268301.htm
-
Vemurafenib
-
-
-
19
-
-
84872061126
-
-
[Internet] Canada H. Vemurafenib. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_zelboraf_148693-eng.php
-
Vemurafenib
-
-
Canada, H.1
-
20
-
-
84900426582
-
Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
-
Hartsough EJ, Basile KJ, Aplin AE. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Molecular cancer research: MCR. 2014; 12: 795-802.
-
(2014)
Molecular cancer research: MCR
, vol.12
, pp. 795-802
-
-
Hartsough, E.J.1
Basile, K.J.2
Aplin, A.E.3
-
21
-
-
84879467934
-
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma
-
Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. The oncologist. 2013; 18: 717-25.
-
(2013)
The oncologist
, vol.18
, pp. 717-725
-
-
Luke, J.J.1
Hodi, F.S.2
-
22
-
-
84947804671
-
-
[Internet] FDA. Dabrafenib. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm354477.htm
-
Dabrafenib
-
-
-
23
-
-
84947809008
-
-
[Internet] FDA. Trametinib. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm354478.htm
-
Trametinib
-
-
-
24
-
-
72049115498
-
KIT as a Therapeutic Target in Melanoma
-
Garrido MC, Bastian BC. KIT as a Therapeutic Target in Melanoma. J Invest Dermatol. 2010; 130: 20-7.
-
(2010)
J Invest Dermatol
, vol.130
, pp. 20-27
-
-
Garrido, M.C.1
Bastian, B.C.2
-
26
-
-
84947792392
-
-
My Cancer Genome
-
[Internet] Lovly C, Sosman J, Pao W. Kit. http://www.mycancergenome.org/content/disease/melanoma/kit/?tab=0 My Cancer Genome
-
Kit
-
-
Lovly, C.1
Sosman, J.2
Pao, W.3
-
27
-
-
57449093330
-
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
-
Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. British journal of cancer. 2008; 99: 2065-9.
-
(2008)
British journal of cancer
, vol.99
, pp. 2065-2069
-
-
Satzger, I.1
Schaefer, T.2
Kuettler, U.3
Broecker, V.4
Voelker, B.5
Ostertag, H.6
-
28
-
-
67149101027
-
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas
-
Smalley KSM, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histology and histopathology. 2009; 24: 643-50.
-
(2009)
Histology and histopathology
, vol.24
, pp. 643-650
-
-
Smalley, K.S.M.1
Sondak, V.K.2
Weber, J.S.3
-
30
-
-
84857760658
-
Sunitinib therapy for melanoma patients with KIT mutations
-
Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18: 1457-63.
-
(2012)
Clinical cancer research: an official journal of the American Association for Cancer Research
, vol.18
, pp. 1457-1463
-
-
Minor, D.R.1
Kashani-Sabet, M.2
Garrido, M.3
O'Day, S.J.4
Hamid, O.5
Bastian, B.C.6
-
31
-
-
0035692448
-
Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets
-
Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer metastasis reviews. 2001; 20: 3-11.
-
(2001)
Cancer metastasis reviews
, vol.20
, pp. 3-11
-
-
Grossman, D.1
Altieri, D.C.2
-
33
-
-
84865841467
-
Chapter Eleven-Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations
-
Keiran SMS, editor. Academic Press
-
Somasundaram R, Villanueva J, Herlyn M. Chapter Eleven-Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations. In: Keiran SMS, editor. Advances in Pharmacology. Academic Press; 2012: 335-59.
-
(2012)
Advances in Pharmacology
, pp. 335-359
-
-
Somasundaram, R.1
Villanueva, J.2
Herlyn, M.3
-
34
-
-
0036176510
-
Mechanisms of cancer drug resistance
-
Gottesman MM. Mechanisms of cancer drug resistance. Annual review of medicine. 2002; 53: 615-27.
-
(2002)
Annual review of medicine
, vol.53
, pp. 615-627
-
-
Gottesman, M.M.1
-
35
-
-
46949085582
-
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure
-
Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittel-Forschung. 2008; 58: 261-4.
-
(2008)
Arzneimittel-Forschung
, vol.58
, pp. 261-264
-
-
Lippert, T.H.1
Ruoff, H.J.2
Volm, M.3
-
36
-
-
84898910635
-
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
-
Chmielowski B. Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. Journal of Skin Cancer. 2013; 2013: 8.
-
(2013)
Journal of Skin Cancer
, vol.2013
, pp. 8
-
-
Chmielowski, B.1
-
37
-
-
84902825664
-
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients
-
Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Science translational medicine. 2014; 6: 238-70.
-
(2014)
Science translational medicine
, vol.6
, pp. 238-270
-
-
Cha, E.1
Klinger, M.2
Hou, Y.3
Cummings, C.4
Ribas, A.5
Faham, M.6
-
38
-
-
84873728334
-
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
-
Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013; 494: 251-5.
-
(2013)
Nature
, vol.494
, pp. 251-255
-
-
Das Thakur, M.1
Salangsang, F.2
Landman, A.S.3
Sellers, W.R.4
Pryer, N.K.5
Levesque, M.P.6
-
39
-
-
84891898344
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
-
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer discovery. 2014; 4: 80-93.
-
(2014)
Cancer discovery
, vol.4
, pp. 80-93
-
-
Shi, H.1
Hugo, W.2
Kong, X.3
Hong, A.4
Koya, R.C.5
Moriceau, G.6
-
40
-
-
84864994126
-
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma
-
Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. The Journal of biological chemistry. 2012; 287: 28087-98.
-
(2012)
The Journal of biological chemistry
, vol.287
, pp. 28087-28098
-
-
Yadav, V.1
Zhang, X.2
Liu, J.3
Estrem, S.4
Li, S.5
Gong, X.Q.6
-
41
-
-
84911416288
-
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma
-
Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2014; 27: 1154-8.
-
(2014)
Pigment Cell Melanoma Res
, vol.27
, pp. 1154-1158
-
-
Rebecca, V.W.1
Alicea, G.M.2
Paraiso, K.H.3
Lawrence, H.4
Gibney, G.T.5
Smalley, K.S.6
-
42
-
-
84864285794
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
-
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487: 500-4.
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
Morikawa, T.2
Shee, K.3
Barzily-Rokni, M.4
Qian, Z.R.5
Du, J.6
-
43
-
-
84890417671
-
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
-
Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of dermatological treatment. 2014; 25: 401-8.
-
(2014)
The Journal of dermatological treatment
, vol.25
, pp. 401-408
-
-
Ma, C.1
Armstrong, A.W.2
-
44
-
-
84921433398
-
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma
-
Ascierto PA, Bastholt L, Hersey P, Cinat G, Eggermont AM, Hauschild A, et al. Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. American journal of therapeutics. 2015;22:44-53.
-
(2015)
American journal of therapeutics
, vol.22
, pp. 44-53
-
-
Ascierto, P.A.1
Bastholt, L.2
Hersey, P.3
Cinat, G.4
Eggermont, A.M.5
Hauschild, A.6
-
45
-
-
39749104201
-
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion
-
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008; 112: 982-94.
-
(2008)
Cancer
, vol.112
, pp. 982-994
-
-
Hauschild, A.1
Gogas, H.2
Tarhini, A.3
Middleton, M.R.4
Testori, A.5
Dreno, B.6
-
47
-
-
84878451069
-
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
-
Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013; 24: 1691-7.
-
(2013)
Ann Oncol
, vol.24
, pp. 1691-1697
-
-
Boussemart, L.1
Routier, E.2
Mateus, C.3
Opletalova, K.4
Sebille, G.5
Kamsu-Kom, N.6
-
48
-
-
72949113024
-
Stromal cells and integrins: conforming to the needs of the tumor microenvironment
-
Alphonso A, Alahari SK. Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia. 2009; 11: 1264-71.
-
(2009)
Neoplasia
, vol.11
, pp. 1264-1271
-
-
Alphonso, A.1
Alahari, S.K.2
-
49
-
-
28844444157
-
Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy
-
Micke P, Ostman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert opinion on therapeutic targets. 2005; 9: 1217-33.
-
(2005)
Expert opinion on therapeutic targets
, vol.9
, pp. 1217-1233
-
-
Micke, P.1
Ostman, A.2
-
50
-
-
18844428327
-
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
-
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121: 335-48.
-
(2005)
Cell
, vol.121
, pp. 335-348
-
-
Orimo, A.1
Gupta, P.B.2
Sgroi, D.C.3
Arenzana-Seisdedos, F.4
Delaunay, T.5
Naeem, R.6
-
51
-
-
77956883321
-
Activation of fibroblasts in cancer stroma
-
Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Experimental cell research. 2010; 316: 2713-22.
-
(2010)
Experimental cell research
, vol.316
, pp. 2713-2722
-
-
Rasanen, K.1
Vaheri, A.2
-
52
-
-
38849141696
-
Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
-
Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression. Cancer Res. 2008; 68: 918-26.
-
(2008)
Cancer Res
, vol.68
, pp. 918-926
-
-
Hwang, R.F.1
Moore, T.2
Arumugam, T.3
Ramachandran, V.4
Amos, K.D.5
Rivera, A.6
-
53
-
-
0033215242
-
Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium
-
Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium. Cancer Res. 1999; 59: 5002-11.
-
(1999)
Cancer Res
, vol.59
, pp. 5002-5011
-
-
Olumi, A.F.1
Grossfeld, G.D.2
Hayward, S.W.3
Carroll, P.R.4
Tlsty, T.D.5
Cunha, G.R.6
-
54
-
-
0025868178
-
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression
-
Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 1991; 88: 6028-32.
-
(1991)
Proceedings of the National Academy of Sciences of the United States of America
, vol.88
, pp. 6028-6032
-
-
Cornil, I.1
Theodorescu, D.2
Man, S.3
Herlyn, M.4
Jambrosic, J.5
Kerbel, R.S.6
-
55
-
-
72849125358
-
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
-
Santos AM, Jung J, Aziz N, Kissil JL, Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. The Journal of clinical investigation. 2009; 119: 3613-25.
-
(2009)
The Journal of clinical investigation
, vol.119
, pp. 3613-3625
-
-
Santos, A.M.1
Jung, J.2
Aziz, N.3
Kissil, J.L.4
Pure, E.5
-
56
-
-
80054926267
-
Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1
-
Shao H, Cai L, Grichnik JM, Livingstone AS, Velazquez OC, Liu ZJ. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene. 2011; 30: 4316-26.
-
(2011)
Oncogene
, vol.30
, pp. 4316-4326
-
-
Shao, H.1
Cai, L.2
Grichnik, J.M.3
Livingstone, A.S.4
Velazquez, O.C.5
Liu, Z.J.6
-
57
-
-
0035890359
-
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling
-
Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, et al. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res. 2001; 61: 8306-16.
-
(2001)
Cancer Res
, vol.61
, pp. 8306-8316
-
-
Berking, C.1
Takemoto, R.2
Schaider, H.3
Showe, L.4
Satyamoorthy, K.5
Robbins, P.6
-
58
-
-
0027987173
-
Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts
-
Coucke P, Baramova E, Leprince P, Depauwgillet M, Foidart J, Bassleer R. Metalloproteinases and serine proteases activities in mixed spheroids of mouse b16 melanoma-cells and fibroblasts. International journal of oncology. 1994; 5: 1125-30.
-
(1994)
International journal of oncology
, vol.5
, pp. 1125-1130
-
-
Coucke, P.1
Baramova, E.2
Leprince, P.3
Depauwgillet, M.4
Foidart, J.5
Bassleer, R.6
-
59
-
-
84901020848
-
Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment
-
Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Frontiers in oncology. 2014; 4: 63
-
(2014)
Frontiers in oncology
, vol.4
, pp. 63
-
-
Augsten, M.1
-
61
-
-
66849093706
-
On the origin of cancer-associated fibroblasts
-
Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle. 2009; 8: 1461-2.
-
(2009)
Cell Cycle
, vol.8
, pp. 1461-1462
-
-
Anderberg, C.1
Pietras, K.2
-
62
-
-
75849159205
-
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression
-
Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Seminars in cell & developmental biology. 2010; 21: 19-25.
-
(2010)
Seminars in cell & developmental biology
, vol.21
, pp. 19-25
-
-
Shimoda, M.1
Mellody, K.T.2
Orimo, A.3
-
63
-
-
84857640591
-
Cancer associated fibroblasts: the dark side of the coin
-
Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. American journal of cancer research. 2011; 1: 482-97.
-
(2011)
American journal of cancer research
, vol.1
, pp. 482-497
-
-
Cirri, P.1
Chiarugi, P.2
-
64
-
-
79952392467
-
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
-
Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011; 17: 320-9.
-
(2011)
Nat Med
, vol.17
, pp. 320-329
-
-
Bissell, M.J.1
Hines, W.C.2
-
66
-
-
23744452875
-
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP-and HGF-mediated signaling networks
-
Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP-and HGF-mediated signaling networks. Oncogene. 2005; 24: 5053-68.
-
(2005)
Oncogene
, vol.24
, pp. 5053-5068
-
-
Cheng, N.1
Bhowmick, N.A.2
Chytil, A.3
Gorksa, A.E.4
Brown, K.A.5
Muraoka, R.6
-
67
-
-
58949102960
-
Modulated expression of WFDC1 during carcinogenesis and cellular senescence
-
Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, et al. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 2009; 30: 20-7.
-
(2009)
Carcinogenesis
, vol.30
, pp. 20-27
-
-
Madar, S.1
Brosh, R.2
Buganim, Y.3
Ezra, O.4
Goldstein, I.5
Solomon, H.6
-
69
-
-
34447276000
-
Tumor microenvironment: the role of the tumor stroma in cancer
-
Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. Journal of cellular biochemistry. 2007; 101: 805-15.
-
(2007)
Journal of cellular biochemistry
, vol.101
, pp. 805-815
-
-
Li, H.1
Fan, X.2
Houghton, J.3
-
70
-
-
3042697038
-
Hyaluronan: from extracellular glue to pericellular cue
-
Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004; 4: 528-39.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 528-539
-
-
Toole, B.P.1
-
71
-
-
50149105712
-
Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression
-
Itano N, Zhuo L, Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer science. 2008; 99: 1720-5.
-
(2008)
Cancer science
, vol.99
, pp. 1720-1725
-
-
Itano, N.1
Zhuo, L.2
Kimata, K.3
-
72
-
-
0034492932
-
Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma
-
Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. The American journal of pathology. 2000; 157: 957-65.
-
(2000)
The American journal of pathology
, vol.157
, pp. 957-965
-
-
Karjalainen, J.M.1
Tammi, R.H.2
Tammi, M.I.3
Eskelinen, M.J.4
Agren, U.M.5
Parkkinen, J.J.6
-
73
-
-
20144385541
-
Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2
-
Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. The Journal of biological chemistry. 2005; 280: 20310-5.
-
(2005)
The Journal of biological chemistry
, vol.280
, pp. 20310-20315
-
-
Misra, S.1
Ghatak, S.2
Toole, B.P.3
-
75
-
-
23444445895
-
Hyaluronan metabolism: a major paradox in cancer biology
-
Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathologie-biologie. 2005; 53: 372-82.
-
(2005)
Pathologie-biologie
, vol.53
, pp. 372-382
-
-
Stern, R.1
-
76
-
-
84875945044
-
Biological Characteristics and Genetic Heterogeneity between Carcinoma-Associated Fibroblasts and Their Paired Normal Fibroblasts in Human Breast Cancer
-
Peng QL, Zhao LY, Hou YX, Sun Y, Wang LY, Luo HJ, et al. Biological Characteristics and Genetic Heterogeneity between Carcinoma-Associated Fibroblasts and Their Paired Normal Fibroblasts in Human Breast Cancer. Plos One. 2013; 8.
-
(2013)
Plos One
, pp. 8
-
-
Peng, Q.L.1
Zhao, L.Y.2
Hou, Y.X.3
Sun, Y.4
Wang, L.Y.5
Luo, H.J.6
-
77
-
-
84892917277
-
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction
-
Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. British journal of cancer. 2014; 110: 469-78.
-
(2014)
British journal of cancer
, vol.110
, pp. 469-478
-
-
Nagasaki, T.1
Hara, M.2
Nakanishi, H.3
Takahashi, H.4
Sato, M.5
Takeyama, H.6
-
78
-
-
69449095344
-
Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer
-
Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Molecular cancer research: MCR. 2009; 7: 1212-23.
-
(2009)
Molecular cancer research: MCR
, vol.7
, pp. 1212-1223
-
-
Paland, N.1
Kamer, I.2
Kogan-Sakin, I.3
Madar, S.4
Goldfinger, N.5
Rotter, V.6
-
79
-
-
49749144117
-
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation-Implications for the response to hormonal therapy
-
Mercier I, Casimiro MC, Wang CG, Rosenberg AL, Quong J, Minkeu A, et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation-Implications for the response to hormonal therapy. Cancer Biology & Therapy. 2008; 7: 1212-25.
-
(2008)
Cancer Biology & Therapy
, vol.7
, pp. 1212-1225
-
-
Mercier, I.1
Casimiro, M.C.2
Wang, C.G.3
Rosenberg, A.L.4
Quong, J.5
Minkeu, A.6
-
80
-
-
84867095073
-
The architecture of fibroblast monolayers of different origin differentially influences tumor cell growth
-
Flaberg E, Guven H, Savchenko A, Pavlova T, Kashuba V, Szekely L, et al. The architecture of fibroblast monolayers of different origin differentially influences tumor cell growth. International Journal of Cancer. 2012; 131: 2274-83.
-
(2012)
International Journal of Cancer
, vol.131
, pp. 2274-2283
-
-
Flaberg, E.1
Guven, H.2
Savchenko, A.3
Pavlova, T.4
Kashuba, V.5
Szekely, L.6
-
81
-
-
84900319246
-
[Carcinoma-associated fibroblasts in cancer: the great escape]
-
Albrengues J, Meneguzzi G, Gaggioli C. [Carcinoma-associated fibroblasts in cancer: the great escape]. Med Sci (Paris). 2014; 30: 391-7.
-
(2014)
Med Sci (Paris)
, vol.30
, pp. 391-397
-
-
Albrengues, J.1
Meneguzzi, G.2
Gaggioli, C.3
-
82
-
-
82955172970
-
Fibroblasts contribute to melanoma tumor growth and drug resistance
-
Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts contribute to melanoma tumor growth and drug resistance. Molecular pharmaceutics. 2011; 8: 2039-49.
-
(2011)
Molecular pharmaceutics
, vol.8
, pp. 2039-2049
-
-
Flach, E.H.1
Rebecca, V.W.2
Herlyn, M.3
Smalley, K.S.4
Anderson, A.R.5
-
83
-
-
0033105730
-
Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis-the role of platelet-derived growth factor
-
Godden JL, Edward M, MacKie RM. Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis-the role of platelet-derived growth factor. Eur J Cancer. 1999; 35: 473-80.
-
(1999)
Eur J Cancer
, vol.35
, pp. 473-480
-
-
Godden, J.L.1
Edward, M.2
MacKie, R.M.3
-
85
-
-
84885014865
-
Tumor-stromal interactions with direct cell contacts enhance motility of non-small cell lung cancer cells through the hedgehog signaling pathway
-
Choe C, Shin YS, Kim SH, Jeon MJ, Choi SJ, Lee J, et al. Tumor-stromal interactions with direct cell contacts enhance motility of non-small cell lung cancer cells through the hedgehog signaling pathway. Anticancer research. 2013; 33: 3715-23.
-
(2013)
Anticancer research
, vol.33
, pp. 3715-3723
-
-
Choe, C.1
Shin, Y.S.2
Kim, S.H.3
Jeon, M.J.4
Choi, S.J.5
Lee, J.6
-
86
-
-
0033838767
-
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors
-
Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. The American journal of pathology. 2000; 156: 1515-25.
-
(2000)
The American journal of pathology
, vol.156
, pp. 1515-1525
-
-
Hsu, M.Y.1
Meier, F.E.2
Nesbit, M.3
Hsu, J.Y.4
Van Belle, P.5
Elder, D.E.6
-
87
-
-
84947729625
-
E-Cadherin Is the Major Mediator of Human Melanocyte Adhesion to Keratinocytes in-Vitro
-
Tang A, Eller MS, Hara M, Yaar M, Hirohashi S, Gilchrest BA. E-Cadherin Is the Major Mediator of Human Melanocyte Adhesion to Keratinocytes in-Vitro. J Invest Dermatol. 1994; 102: 536.
-
(1994)
J Invest Dermatol
, vol.102
, pp. 536
-
-
Tang, A.1
Eller, M.S.2
Hara, M.3
Yaar, M.4
Hirohashi, S.5
Gilchrest, B.A.6
-
88
-
-
0035328628
-
N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells
-
Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001; 61: 3819-25.
-
(2001)
Cancer Res
, vol.61
, pp. 3819-3825
-
-
Li, G.1
Satyamoorthy, K.2
Herlyn, M.3
-
89
-
-
84883343415
-
E-to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression
-
Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T. E-to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Brit J Dermatol. 2013; 169: 618-28.
-
(2013)
Brit J Dermatol
, vol.169
, pp. 618-628
-
-
Lade-Keller, J.1
Riber-Hansen, R.2
Guldberg, P.3
Schmidt, H.4
Hamilton-Dutoit, S.J.5
Steiniche, T.6
-
90
-
-
84861594264
-
Cadherin switch from E-to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail
-
Hao L, Ha JR, Kuzel P, Garcia E, Persad S. Cadherin switch from E-to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Brit J Dermatol. 2012; 166: 1184-97.
-
(2012)
Brit J Dermatol
, vol.166
, pp. 1184-1197
-
-
Hao, L.1
Ha, J.R.2
Kuzel, P.3
Garcia, E.4
Persad, S.5
-
91
-
-
84891757812
-
CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment
-
Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells. 2014; 32: 145-56.
-
(2014)
Stem Cells
, vol.32
, pp. 145-156
-
-
Kinugasa, Y.1
Matsui, T.2
Takakura, N.3
-
92
-
-
84883470829
-
Mesenchymal CD44 Expression Contributes to the Acquisition of an Activated Fibroblast Phenotype via TWIST Activation in the Tumor Microenvironment
-
Spaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. Mesenchymal CD44 Expression Contributes to the Acquisition of an Activated Fibroblast Phenotype via TWIST Activation in the Tumor Microenvironment. Cancer Res. 2013; 73: 5347-59.
-
(2013)
Cancer Res
, vol.73
, pp. 5347-5359
-
-
Spaeth, E.L.1
Labaff, A.M.2
Toole, B.P.3
Klopp, A.4
Andreeff, M.5
Marini, F.C.6
-
93
-
-
84947806628
-
Cancer-associated fibroblasts (CAF) expressing CD44 high increased the aggressiveness of cancer cells. AACR International Conference on Translational Cancer Medicine
-
Shim S, Hah J, Sung M. Cancer-associated fibroblasts (CAF) expressing CD44 high increased the aggressiveness of cancer cells. AACR International Conference on Translational Cancer Medicine. San Francisco, CA: Clin Cancer Res 2010; 2010: A6.
-
(2010)
San Francisco, CA: Clin Cancer Res
, vol.2010
, pp. A6
-
-
Shim, S.1
Hah, J.2
Sung, M.3
-
94
-
-
84859949610
-
The extracellular matrix: a dynamic niche in cancer progression
-
Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. The Journal of cell biology. 2012; 196: 395-406.
-
(2012)
The Journal of cell biology
, vol.196
, pp. 395-406
-
-
Lu, P.1
Weaver, V.M.2
Werb, Z.3
-
95
-
-
0343415583
-
Fibroblasts surrounding melanoma express elevated levels of matrix metalloproteinase-1 (MMP-1) and intercellular adhesion molecule-1 (ICAM-1) in vitro
-
Wandel E, Grasshoff A, Mittag M, Haustein UF, Saalbach A. Fibroblasts surrounding melanoma express elevated levels of matrix metalloproteinase-1 (MMP-1) and intercellular adhesion molecule-1 (ICAM-1) in vitro. Experimental dermatology. 2000; 9: 34-41.
-
(2000)
Experimental dermatology
, vol.9
, pp. 34-41
-
-
Wandel, E.1
Grasshoff, A.2
Mittag, M.3
Haustein, U.F.4
Saalbach, A.5
-
96
-
-
0344442797
-
Influence of cultured dermal fibroblasts on human melanoma cell proliferation, matrix metalloproteinase-2 (MMP-2) expression and invasion in vitro
-
Ntayi C, Hornebeck W, Bernard P. Influence of cultured dermal fibroblasts on human melanoma cell proliferation, matrix metalloproteinase-2 (MMP-2) expression and invasion in vitro. Archives of dermatological research. 2003; 295: 236-41.
-
(2003)
Archives of dermatological research
, vol.295
, pp. 236-241
-
-
Ntayi, C.1
Hornebeck, W.2
Bernard, P.3
-
97
-
-
15044364789
-
High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms
-
Loffek S, Zigrino P, Angel P, Anwald B, Krieg T, Mauch C. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. J Invest Dermatol. 2005; 124: 638-43.
-
(2005)
J Invest Dermatol
, vol.124
, pp. 638-643
-
-
Loffek, S.1
Zigrino, P.2
Angel, P.3
Anwald, B.4
Krieg, T.5
Mauch, C.6
-
98
-
-
84896914323
-
Noncanonical activation of Notch1 protein by membrane type 1 matrix metalloproteinase (MT1-MMP) controls melanoma cell proliferation
-
Ma J, Tang X, Wong P, Jacobs B, Borden EC, Bedogni B. Noncanonical activation of Notch1 protein by membrane type 1 matrix metalloproteinase (MT1-MMP) controls melanoma cell proliferation. The Journal of biological chemistry. 2014; 289: 8442-9.
-
(2014)
The Journal of biological chemistry
, vol.289
, pp. 8442-8449
-
-
Ma, J.1
Tang, X.2
Wong, P.3
Jacobs, B.4
Borden, E.C.5
Bedogni, B.6
-
99
-
-
77954939848
-
MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation
-
Meierjohann S, Hufnagel A, Wende E, Kleinschmidt MA, Wolf K, Friedl P, et al. MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. Molecular cancer. 2010; 9: 201.
-
(2010)
Molecular cancer
, vol.9
, pp. 201
-
-
Meierjohann, S.1
Hufnagel, A.2
Wende, E.3
Kleinschmidt, M.A.4
Wolf, K.5
Friedl, P.6
-
100
-
-
0037318082
-
Fibroblast Activation Protein: Differential Expression and Serine Protease Activity in Reactive Stromal Fibroblasts of Melanocytic Skin Tumors
-
Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, et al. Fibroblast Activation Protein: Differential Expression and Serine Protease Activity in Reactive Stromal Fibroblasts of Melanocytic Skin Tumors. J Investig Dermatol. 2003; 120: 182-8.
-
(2003)
J Investig Dermatol
, vol.120
, pp. 182-188
-
-
Huber, M.A.1
Kraut, N.2
Park, J.E.3
Schubert, R.D.4
Rettig, W.J.5
Peter, R.U.6
-
101
-
-
84863116741
-
Fibroblast activation protein: A potential therapeutic target in cancer
-
Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther. 2012; 13: 123-9.
-
(2012)
Cancer Biol Ther
, vol.13
, pp. 123-129
-
-
Liu, R.1
Li, H.2
Liu, L.3
Yu, J.4
Ren, X.5
-
102
-
-
79956004586
-
Ultraviolet exposure of melanoma cells induces fibroblast activation protein-alpha in fibroblasts: Implications for melanoma invasion
-
Waster P, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-alpha in fibroblasts: Implications for melanoma invasion. International journal of oncology. 2011; 39: 193-202.
-
(2011)
International journal of oncology
, vol.39
, pp. 193-202
-
-
Waster, P.1
Rosdahl, I.2
Gilmore, B.F.3
Seifert, O.4
-
103
-
-
84947756081
-
Modulating the Tumor Microenvironment
-
Gajewski TF, Hodi FS, editors. Springer New York
-
Ruby C, Kaufman H. Modulating the Tumor Microenvironment. In: Gajewski TF, Hodi FS, editors. Targeted Therapeutics in Melanoma. Springer New York; 2012: 353-69.
-
(2012)
Targeted Therapeutics in Melanoma
, pp. 353-369
-
-
Ruby, C.1
Kaufman, H.2
-
104
-
-
84864039745
-
Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness
-
Comito G, Giannoni E, Di Gennaro P, Segura CP, Gerlini G, Chiarugi P. Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. Cancer letters. 2012; 324: 31-41.
-
(2012)
Cancer letters
, vol.324
, pp. 31-41
-
-
Comito, G.1
Giannoni, E.2
Di Gennaro, P.3
Segura, C.P.4
Gerlini, G.5
Chiarugi, P.6
-
105
-
-
84871021675
-
Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness
-
Taddei ML, Giannoni E, Raugei G, Scacco S, Sardanelli AM, Papa S, et al. Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness. Journal of Signal Transduction. 2012; 2012: 10.
-
(2012)
Journal of Signal Transduction
, vol.2012
, pp. 10
-
-
Taddei, M.L.1
Giannoni, E.2
Raugei, G.3
Scacco, S.4
Sardanelli, A.M.5
Papa, S.6
-
106
-
-
62249130824
-
The good and the bad of chemokines/chemokine receptors in melanoma
-
Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment cell & melanoma research. 2009; 22: 175-86.
-
(2009)
Pigment cell & melanoma research
, vol.22
, pp. 175-186
-
-
Richmond, A.1
Yang, J.2
Su, Y.3
-
107
-
-
78649637459
-
Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy
-
Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukocyte Biol. 2011; 89: 31-9.
-
(2011)
J Leukocyte Biol
, vol.89
, pp. 31-39
-
-
Mishra, P.1
Banerjee, D.2
Ben-Baruch, A.3
-
108
-
-
60949112215
-
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth
-
Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106: 3414-9.
-
(2009)
Proceedings of the National Academy of Sciences of the United States of America
, vol.106
, pp. 3414-3419
-
-
Augsten, M.1
Hagglof, C.2
Olsson, E.3
Stolz, C.4
Tsagozis, P.5
Levchenko, T.6
-
109
-
-
0037115647
-
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells
-
Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002; 62: 7328-34.
-
(2002)
Cancer Res
, vol.62
, pp. 7328-7334
-
-
Murakami, T.1
Maki, W.2
Cardones, A.R.3
Fang, H.4
Tun Kyi, A.5
Nestle, F.O.6
-
110
-
-
20144389833
-
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
-
Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11: 1835-41.
-
(2005)
Clinical cancer research: an official journal of the American Association for Cancer Research
, vol.11
, pp. 1835-1841
-
-
Scala, S.1
Ottaiano, A.2
Ascierto, P.A.3
Cavalli, M.4
Simeone, E.5
Giuliano, P.6
-
111
-
-
84947785158
-
Melanoma associated fibroblasts promote melanoma invasiveness: Possible cross talk between CXCR4 and VEGF receptor
-
Giuliano P, Jr., Ierano C, Ascierto PA, Napolitano M, Lombardi M, Liguori M, et al. Melanoma associated fibroblasts promote melanoma invasiveness: Possible cross talk between CXCR4 and VEGF receptor. AACR Meeting Abstracts. 2006; 2006: 42-b.
-
(2006)
AACR Meeting Abstracts
, vol.2006
, pp. 42-b
-
-
Giuliano, P.1
Ierano, C.2
Ascierto, P.A.3
Napolitano, M.4
Lombardi, M.5
Liguori, M.6
-
112
-
-
0142188716
-
CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin
-
Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res. 2003; 63: 6751-7.
-
(2003)
Cancer Res
, vol.63
, pp. 6751-6757
-
-
Cardones, A.R.1
Murakami, T.2
Hwang, S.T.3
-
113
-
-
84877022870
-
Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070
-
O'Boyle G, Swidenbank I, Marshall H, Barker CE, Armstrong J, White SA, et al. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. British journal of cancer. 2013; 108: 1634-40.
-
(2013)
British journal of cancer
, vol.108
, pp. 1634-1640
-
-
O'Boyle, G.1
Swidenbank, I.2
Marshall, H.3
Barker, C.E.4
Armstrong, J.5
White, S.A.6
-
114
-
-
84869226562
-
A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability
-
Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST. A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Molecular cancer therapeutics. 2012; 11: 2516-25.
-
(2012)
Molecular cancer therapeutics
, vol.11
, pp. 2516-2525
-
-
Takekoshi, T.1
Ziarek, J.J.2
Volkman, B.F.3
Hwang, S.T.4
-
115
-
-
20144368873
-
Gene Expression Profiling Reveals Cross-talk between Melanoma and Fibroblasts: Implications for Host-Tumor Interactions in Metastasis
-
Gallagher PG, Bao Y, Prorock A, Zigrino P, Nischt R, Politi V, et al. Gene Expression Profiling Reveals Cross-talk between Melanoma and Fibroblasts: Implications for Host-Tumor Interactions in Metastasis. Cancer Res. 2005; 65: 4134-46.
-
(2005)
Cancer Res
, vol.65
, pp. 4134-4146
-
-
Gallagher, P.G.1
Bao, Y.2
Prorock, A.3
Zigrino, P.4
Nischt, R.5
Politi, V.6
-
116
-
-
70349252148
-
The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo
-
Li L, Dragulev B, Zigrino P, Mauch C, Fox JW. The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. International journal of cancer Journal international du cancer. 2009; 125: 1796-804.
-
(2009)
International journal of cancer Journal international du cancer
, vol.125
, pp. 1796-1804
-
-
Li, L.1
Dragulev, B.2
Zigrino, P.3
Mauch, C.4
Fox, J.W.5
-
117
-
-
84856693628
-
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
-
Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, et al. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer immunology, immunotherapy: CII. 2012; 61: 145-55.
-
(2012)
Cancer immunology, immunotherapy: CII
, vol.61
, pp. 145-155
-
-
Terai, M.1
Eto, M.2
Young, G.D.3
Berd, D.4
Mastrangelo, M.J.5
Tamura, Y.6
-
118
-
-
84887626490
-
Interleukin-6-induced Twist and N-cadherin enhance melanoma cell metastasis
-
Na YR, Lee JS, Lee SJ, Seok SH. Interleukin-6-induced Twist and N-cadherin enhance melanoma cell metastasis. Melanoma research. 2013; 23: 434-43.
-
(2013)
Melanoma research
, vol.23
, pp. 434-443
-
-
Na, Y.R.1
Lee, J.S.2
Lee, S.J.3
Seok, S.H.4
-
119
-
-
44849141362
-
Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study
-
Casey TM, Eneman J, Crocker A, White J, Tessitore J, Stanley M, et al. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study. Breast cancer research and treatment. 2008; 110: 39-49.
-
(2008)
Breast cancer research and treatment
, vol.110
, pp. 39-49
-
-
Casey, T.M.1
Eneman, J.2
Crocker, A.3
White, J.4
Tessitore, J.5
Stanley, M.6
-
121
-
-
0027343406
-
met and HGF-SF in normal melanocytes and melanoma cells
-
Halaban R, Rubin JS, White W. met and HGF-SF in normal melanocytes and melanoma cells. Exs. 1993; 65: 329-39.
-
(1993)
Exs
, vol.65
, pp. 329-339
-
-
Halaban, R.1
Rubin, J.S.2
White, W.3
-
122
-
-
14844334889
-
HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1
-
Gaggioli C, Deckert M, Robert G, Abbe P, Batoz M, Ehrengruber MU, et al. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene. 2005; 24: 1423-33.
-
(2005)
Oncogene
, vol.24
, pp. 1423-1433
-
-
Gaggioli, C.1
Deckert, M.2
Robert, G.3
Abbe, P.4
Batoz, M.5
Ehrengruber, M.U.6
-
123
-
-
79952581666
-
The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators
-
Koefinger P, Wels C, Joshi S, Damm S, Steinbauer E, Beham-Schmid C, et al. The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigment cell & melanoma research. 2011; 24: 382-5.
-
(2011)
Pigment cell & melanoma research
, vol.24
, pp. 382-385
-
-
Koefinger, P.1
Wels, C.2
Joshi, S.3
Damm, S.4
Steinbauer, E.5
Beham-Schmid, C.6
-
124
-
-
0035816677
-
Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail
-
Poser I, Dominguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. The Journal of biological chemistry. 2001; 276: 24661-6.
-
(2001)
The Journal of biological chemistry
, vol.276
, pp. 24661-24666
-
-
Poser, I.1
Dominguez, D.2
de Herreros, A.G.3
Varnai, A.4
Buettner, R.5
Bosserhoff, A.K.6
-
125
-
-
84865359623
-
Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity
-
Cianfarani F, Mastroeni S, Odorisio T, Passarelli F, Cattani C, Mannooranparampil TJ, et al. Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity. Journal of cutaneous pathology. 2012; 39: 826-34.
-
(2012)
Journal of cutaneous pathology
, vol.39
, pp. 826-834
-
-
Cianfarani, F.1
Mastroeni, S.2
Odorisio, T.3
Passarelli, F.4
Cattani, C.5
Mannooranparampil, T.J.6
-
126
-
-
57849117839
-
Tumor-Associated Fibroblasts as "Trojan Horse" Mediators of Resistance to Anti-VEGF Therapy
-
Francia G, Emmenegger U, Kerbel RS. Tumor-Associated Fibroblasts as "Trojan Horse" Mediators of Resistance to Anti-VEGF Therapy. Cancer Cell. 2009; 15: 3-5.
-
(2009)
Cancer Cell
, vol.15
, pp. 3-5
-
-
Francia, G.1
Emmenegger, U.2
Kerbel, R.S.3
-
127
-
-
84947753843
-
The microenvironment is the key determinant of melanoma drug resistance
-
Haass NK, Smalley KS, Herlyn M. The microenvironment is the key determinant of melanoma drug resistance. J Invest Dermatol. 2006; 126: 145.
-
(2006)
J Invest Dermatol
, vol.126
, pp. 145
-
-
Haass, N.K.1
Smalley, K.S.2
Herlyn, M.3
-
128
-
-
84865036227
-
Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death
-
Castells M, Thibault B, Delord JP, Couderc B. Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death. Int J Mol Sci. 2012; 13: 9545-71.
-
(2012)
Int J Mol Sci
, vol.13
, pp. 9545-9571
-
-
Castells, M.1
Thibault, B.2
Delord, J.P.3
Couderc, B.4
-
130
-
-
84947786963
-
Targeting Tumor Associated Fibroblasts Tumor Associated Fibroblasts and Chemotherapy
-
Mueller MM, Fusenig NE, editors. Springer Netherlands
-
Liao D, Reisfeld R. Targeting Tumor Associated Fibroblasts Tumor Associated Fibroblasts and Chemotherapy. In: Mueller MM, Fusenig NE, editors. Tumor-Associated Fibroblasts and their Matrix. Springer Netherlands; 2011: 403-18.
-
(2011)
Tumor-Associated Fibroblasts and their Matrix
, pp. 403-418
-
-
Liao, D.1
Reisfeld, R.2
-
131
-
-
33745837774
-
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
-
Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. Journal of Clinical Investigation. 2006; 116: 1955-62.
-
(2006)
Journal of Clinical Investigation
, vol.116
, pp. 1955-1962
-
-
Loeffler, M.1
Kruger, J.A.2
Niethammer, A.G.3
Reisfeld, R.A.4
-
132
-
-
79953198272
-
The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts
-
Zigrino P, Nischt R, Mauch C. The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts. The Journal of biological chemistry. 2011; 286: 6801-7.
-
(2011)
The Journal of biological chemistry
, vol.286
, pp. 6801-6807
-
-
Zigrino, P.1
Nischt, R.2
Mauch, C.3
-
133
-
-
84907060803
-
Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin
-
Tiago M, de Oliveira EM, Brohem CA, Pennacchi PC, Paes RD, Haga RB, et al. Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin. Tissue engineering Part A. 2014; 20: 2412-21.
-
(2014)
Tissue engineering Part A
, vol.20
, pp. 2412-2421
-
-
Tiago, M.1
de Oliveira, E.M.2
Brohem, C.A.3
Pennacchi, P.C.4
Paes, R.D.5
Haga, R.B.6
-
134
-
-
75849116069
-
Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy?
-
Gonda TA, Varro A, Wang TC, Tycko B. Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy? Seminars in cell & developmental biology. 2010; 21: 2-10.
-
(2010)
Seminars in cell & developmental biology
, vol.21
, pp. 2-10
-
-
Gonda, T.A.1
Varro, A.2
Wang, T.C.3
Tycko, B.4
-
135
-
-
77951233373
-
Cancer associated fibroblasts (CAFs) in tumor microenvironment
-
Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 2010; 15: 166-79.
-
(2010)
Front Biosci (Landmark Ed)
, vol.15
, pp. 166-179
-
-
Xing, F.1
Saidou, J.2
Watabe, K.3
-
136
-
-
84875234222
-
Carcinoma-associated fibroblasts are a promising therapeutic target
-
Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers. 2013; 5: 149-69.
-
(2013)
Cancers
, vol.5
, pp. 149-169
-
-
Togo, S.1
Polanska, U.M.2
Horimoto, Y.3
Orimo, A.4
-
137
-
-
84862001701
-
Inhibition of Fibroblast Growth by Notch1 Signaling Is Mediated by Induction of Wnt11-Dependent WISP-1
-
Liu ZJ, Li Y, Tan YR, Xiao M, Zhang JL, Radtke F, et al. Inhibition of Fibroblast Growth by Notch1 Signaling Is Mediated by Induction of Wnt11-Dependent WISP-1. Plos One. 2012; 7.
-
(2012)
Plos One
, pp. 7
-
-
Liu, Z.J.1
Li, Y.2
Tan, Y.R.3
Xiao, M.4
Zhang, J.L.5
Radtke, F.6
-
138
-
-
28244447726
-
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts
-
Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 2005; 65: 11156-63.
-
(2005)
Cancer Res
, vol.65
, pp. 11156-11163
-
-
Lee, J.1
Fassnacht, M.2
Nair, S.3
Boczkowski, D.4
Gilboa, E.5
-
139
-
-
38849202330
-
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
-
Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. Plos Med. 2008; 5: 123-38.
-
(2008)
Plos Med
, vol.5
, pp. 123-138
-
-
Pietras, K.1
Pahler, J.2
Bergers, G.3
Hanahan, D.4
-
140
-
-
84904499781
-
Melanoma: from melanocyte to genetic alterations and clinical options
-
Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica. 2013; 2013: 635203.
-
(2013)
Scientifica
, vol.2013
-
-
Bertolotto, C.1
|